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Background
The Colitis Once Daily Asacol
® (CODA) study assessed
the efficacy and safety of once daily (OD) dosing with
Mesalazine (Asacol
®, 2.4g as 3 x 800mg tablets) versus
one 800mg tablet three times daily (TDS) over a 12
month period for patients in remission with ulcerative
colitis (UC). Emerging evidence suggests OD Mesalazine
is as effective as divided doses [1]. While this has been
attributed to better adherence, detailed measures of
adherence have been lacking in previous studies. A sub
study was run alongside in order to provide a more
intense monitoring of adherence using the Medication
Event Monitoring System (MEMS).
Objectives
T o( i . )d e s c r i b et h eu s eo ft h eM E M Sf o rad e t a i l e d
assessment of medication adherence and (ii.) present
results from the CODA sub study, comparing adherence
data collected using the MEMS with the methods used
in the main trial.
Methods
The main CODA trial collected tablet counts at patient
visits and asked questions on perceived adherence. The
CODA sub study used the MEMS cap data, which elec-
tronically recorded the time and date of each cap open-
ing. It was assumed that each cap opening represented a
patient taking the correct medication from the bottle
[2].
Results
A total of 58 patients had usable adherence data (49
with complete data (12 months or until relapse), 9 with
partial data, 3 patients were withdrawn). The frequency
of cap openings split by trial arm will be presented. The
percentage of days adherent was significantly different
between the two trial arms, with OD patients consider-
ably more adherent than TDS patients. The impact of
controlling for adherence on relapse rates will be pre-
sented. A comparison will be made between the MEMS
adherence data and the adherence data obtained in the
main trial. More detailed analysis of patient adherence;
including (i.) weekday versus weekend adherence; (ii.)
adherence around visit dates versus regular adherence
and (iii.) patterns of adherence over time will be
considered.
Conclusions
Collecting adherence data electronically using products
such as the MEMS provides an adequate representation
of the complexities of patient adherence that may not
be possible to obtain through other means (e.g. tablet
counts and patient perception).
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